In-Pharma-tion ESR workshop

Online, 14. – 15. October 2021

InPharma consists of 11 Beneficiaries who will employ the 13 Early Stage Resarchers (ESRs) uniting world-leading academic research groups and pharma companies on their common search for better drug formulation processes which lead to safer and more efficient drugs for patients while simultaneously eradicating animal testing from the process and reducing development costs.

Day 1: Introduction to industrial challenges and different computational tools to model formulations

 

Morning session on industrial challenges with a brief overview of computational modeling of formulations

9:00–9:15

Welcome address to this ESR workshop in Basel
Prof. Brendan Griffin, University College Cork & Prof. Martin Kuentz, FHNW

9:15–10:00

Introduction to challenges in pharmaceutical drug profiling
Dr. Nicole Wyttenbach, Roche Ltd.

10:00–10:45

Introduction to pharmaceutical solid state characterization
Dr. Rolf Hilfiker, Solvias Ltd.

10:45–11:00

Break

11:00–11.45

Overview of different computational approaches to study drug-excipient interactions
Prof. Martin Kuentz, FHNW

11:45–13:00

Lunch break

 

Afternoon session on individual tools of computational pharmaceutics

13:00–13:45

Machine learning in selected pharmaceutical applications
Prof. Markus Lill, University of Basel

13:45–14:30

COSMO-RS model to aid with selection of excipients
Dr. Daniel Price, Merck KGaA

14:30–14:45

Break

14:45–15:30

Molecular dynamics simulations in pharmaceutical material science
Dr. Jacob Gavartin, Schrödinger Inc.

15:30–16:15

Opportunities of in silico property prediction
Dr. Jon Christensen, Hafnium Labs

16:15–16:45

Wrap-up and discussion
All participants


Day 2 : Introduction to biopharmaceutical challenges and physiologically-based pharmacokinetic (PBPK) modeling in pharmaceutics

 

Morning session on biopharmaceutical challenges and an overview of PBPK tools

9:00–9:45

Challenges of oral delivery and from BCS to rDCS
Prof. Jennifer Dressman, Fraunhofer Institute Frankfurt

9:45–10:30

Challenges in special patient populations
Prof. Maria Vertzoni, National and Kapodistrian University of Athens

10:30–10:45

Break

10:45–11:30

Physiologically-based absorption modeling
Dr. André Dallman, Bayer AG

11:30–13:00

Lunch break

 

Afternoon session on PBPK modeling applications

13:00–13:45

The Simcyp- approach to absorption modeling
Dr. David B. Turner, Certara

13:45–14:30

Industrial case studies of using PBPK modeling
Dr. Xavier Pepin, Astra Zeneca

14:30–15:15

PBPK modeling in a regulatory environment
Dr. Paul Seo, FDA

15:15–16:00

Wrap-up and discussion
All participants

Main contacts


Prof. Martin Kuentz, FHNW
Main organiser


Prof. Brendan Griffin, University College Cork

InPharma Coordinator

Go to section